Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
19.45
+0.44 (2.31%)
At close: Oct 15, 2026, 4:00 PM EDT
19.47
+0.02 (0.10%)
After-hours: Oct 15, 2026, 7:45 PM EDT
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,029 employees as of March 31, 2026. The number of employees decreased by 426 or -0.90% compared to the previous year.
Employees
47,029
Change (1Y)
-426
Growth (1Y)
-0.90%
Revenue / Employee
$604,230
Profits / Employee
-$21,380
Market Cap
62.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 47,029 | -426 | -0.90% |
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Alkermes | 2,050 |
TAK News
- 23 hours ago - Takeda’s ORZEYFUL launches in Japan and China - TheFly
- 1 day ago - Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 - Business Wire
- 1 day ago - Takeda announces Phase 2/3 IgGNITE trial met primary endpoint - TheFly
- 1 day ago - Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 - Business Wire
- 15 days ago - Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib - TheFly
- 15 days ago - Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib - TheFly
- 15 days ago - Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial - Nasdaq
- 15 days ago - Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial - Nasdaq